Dr. Rajiv Anand, MD

Dr. Anand practices at Texas Retina Associates in Dallas, Texas.

Dr. Anand's NPI, 1508865254, was assigned on July 15, 2005. Dr. Anand graduated from Delhi University College of Medical Sciences in 1978. Dr. Anand holds Texas license H5505.

Dr. Anand's primary practice is Texas Retina Associates, at 9600 N Central Expy, Dallas, TX 75231 in Dallas County. The practice phone is (214) 692-6941.

Dr. Anand's primary practice is Texas Retina Associates in Dallas, Texas. Dmand AI also links Dr. Anand to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Anand practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Anand's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Anand is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Anand's licenses on file in 2 states: Texas and Pennsylvania.

Dmand AI lists age-related macular degeneration, cataract, dry eye, eyelid inflammation, glaucoma, hypertensive retinopathy, inflammation of iris and laser destruction of retinal or choroid lesions among the conditions Dr. Anand treats.

CMS data shows 19,463 Medicare services from Dr. Anand across 18 procedure codes in 2024, for 1,154 Medicare patients. Medicare paid $1,313,217 for them.

CMS counts 1,154 Medicare patients who saw Dr. Anand in 2024. The largest group is 75 to 84, with 494 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.34, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Anand's median patient age at 73, with 53% women.

In 2024, Dr. Anand wrote 380 Medicare Part D claims for 202 patients. 68% of them were for generic drugs. CMS names the drug for 327 of them, across 7 drugs with 11 or more claims each, at $6,292 in total drug cost. In 2023, CMS named 311 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Anand for performance year 2024, reported as part of a group. Dr. Anand accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 32 papers to Dr. Anand, published from 2011 to 2024. 2012 was the busiest year, with 3. The most frequent topics are Visual Acuity, Fundus Oculi and Fluorescein Angiography. Dr. Anand has published most often in Br J Oral Maxillofac Surg. Dr. Anand's most frequent co-authors are Robert A. Sisk, MD, Dwain Fuller, MD and Alessandro Iannaccone, MD.

Dmand AI links Dr. Anand to 1 clinical trial.

CMS Open Payments shows 88 general payments to Dr. Anand from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 49% of the total. Ellex, Inc paid the most, $1,540.

Dmand AI lists 3 awards for Dr. Anand, most recently AAO Fellow in 2013.

Dr. Anand graduated from Delhi University College of Medical Sciences in 1978. Dr. Anand is a member of AAO and TMA.

Dr. Anand is in network with 20 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 15. Check the plan with the practice before a visit.